主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
SGMT
#3052
Sagimet Biosciences Inc. Series A Common Stock
5.7
1
-1.04%
版块:
基础:
利润货币:
日范围
年范围
日变化
-1.04%
每月变动
-6.55%
6个月变化
-26.04%
年变化
+58.17%
前一天收盘价
5.7
7
Open
5.7
1
Bid
Ask
Low
5.7
1
High
5.7
1
交易量
21
市场
股票
医疗保健
SGMT
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2023
2024
TTM
Key stats
Total common shares outstanding
31.91 M
32.2 M
—
Valuation ratios
Enterprise value
—
—
—
Price to earnings ratio
-2
-3.1
-12.76
Price to sales ratio
27.88
—
—
Price to cash flow ratio
2.35
3.32
14.78
Price to book ratio
0.61
0.91
1.88
Enterprise value to EBITDA ratio
—
—
—
Profitability ratios
Return on assets %
-0.29
-0.28
-0.4
Return on equity %
-0.31
-0.29
-0.42
Return on invested capital %
-108.46 K
-6 666
—
Gross margin %
100
—
—
Operating margin %
-1 537
—
—
EBITDA margin %
—
—
—
Net margin %
-1 393.8
—
—
Liquidity ratios
Quick ratio
—
—
—
Current ratio
17.09
34.3
85.33
Inventory turnover
—
—
—
Asset turnover
0.02
—
—
Solvency ratios
Debt to assets ratio
—
—
—
Debt to equity ratio
—
—
—
Long term debt to total assets ratio
—
—
—
Long term debt to total equity ratio
—
—
—
Per share metrics
Operating cash flow per share
-2.27
-1.35
-1.4
EBIT per share
—
—
—
EBITDA per share
—
—
—
Total debt per share
—
—
—
Cash per share
9.07
5.06
17.65
Net current asset value per share
9.24
4.87
17.06
Tangible book value per share
8.71
4.97
17.02
Working capital per share
8.7
4.73
16.19
Book value per share
8.71
4.97
17.02
新闻
Sagimet生物科学股票在痤疮药物安全性数据积极后上涨
Sagimet stock rises after positive Phase 3 safety data for acne drug
Ascletis reports positive long-term safety data for acne drug denifanstat
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT)
Sagimet reports positive Phase 1 results for MASH combination therapy
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
歌礼制药-B(01672):同类首创FASN抑制剂地尼法司他(ASC40)治疗痤疮的新药上市申请获国家药监局受理
Sagimet Biosciences executive chairman sells $290k in shares
Citizens上调Sagimet Biosciences目标价至35美元
Sagimet Biosciences stock price target raised to $35 by Citizens
丹尼凡斯塔特在中国的第三期痤疮临床试验中达到所有终点
Denifanstat meets all endpoints in phase 3 acne trial in China